Framework Journal · one stock, one dated entry

Recorded 2025-12-31 · Permanent

Curanex Pharmaceuticals Inc CURX

Clears both ethical standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases.

The label
Accumulation

read at $0.21

Curanex Pharmaceuticals Inc holds its Accumulation at $0.21.

PHINPOOPSC
  • PHPhase · the trend structure carries the Accumulation label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · screen not yet scored
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 16 days
Price$0.21
ValuationN/A trailing · N/A forward price to earnings
Values screenNot scored · score 70.0
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Profit margin0.0%
currently unprofitable
Return on equity-85.2%
not currently earning a positive return on equity
Debt to equity1.56
a meaningful debt load worth watching
Current ratio9.37
comfortably covers its short-term bills
Market cap$6M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in CURX's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 35.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 16%. Entered 2026-07-25 · Markdown

The dated journal · newest first, never edited

2026-07-25 Markdown $0.21 -35.9% Entry 4

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 35.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 16%.

2026-07-18 Markdown $0.32 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 16%.

2026-07-03 Markdown $0.32 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Markdown $0.32 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $0.33 -3.2% · $969 -3.2%
2 months $0.46 -31.1% · $689 -31.1%
3 months $0.38 -17.0% · $830 -17.0%
6 months $0.46 -30.5% · $695 -30.5%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever CURX does next, these words stay.

Curanex Pharmaceuticals Inc · CURX · Accumulation · $0.21
Recorded 2025-12-31 · before the outcome · scored mechanically

Get our weekly market brief free.